Medicenna Therapeutics (MDNA) investor relations material

Introduction and agenda

• KOL webinar scheduled for Nov. 10, 2026, to discuss SITC results, melanoma and endometrial cohort data, and MDNA11’s development potential.

• ABILITY-1 is a Phase 1/2 study evaluating MDNA11 alone or with pembrolizumab in advanced solid tumors resistant to approved therapies; discussion covered study design, results, and future directions.

KOL background and credentials

• Hussein A. Tawbi is an MD Anderson melanoma and immuno-oncology drug-development leader who has worked in the field since 2005 and participated in FDA reviews and approvals.

• André Mansinho is Director of Clinical Research at START Lisbon and an ABILITY-1 principal investigator who enrolled patients; Paolo Ascierto presented the SITC data.

Market insights and analysis

• Post-ICI MSI-H/dMMR GI salvage benchmarks include ~11% ORR for rechallenge, ~12–13% for chemotherapy ± targeted therapy, and ~7–22% for emerging programs; cross-trial comparisons are descriptive.

• Checkpoint response rates fall to 10%–12% after secondary resistance; liver metastases are associated with lower response rates and shorter PFS, while MSI-H GI cancers can show primary resistance or progression after response.

• Cellular therapies such as TIL face patient-selection, access, and treatment-complexity limits; Tawbi viewed biomarker-driven, tumor-agnostic development as a potentially FDA-palatable route, with melanoma-specific development also discussed.